This trial is completed!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Scorpion Sting Envenomation
and you are
between 6 and 18
years old
Phase
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

There is no FDA approved therapy for the treatment of scorpion envenomation in the United States. Centruroides scorpion envenomation produces a pattern of neurotoxicity with a spectrum of severity ranging from trivial to life threatening. Patients stung by Centruroides scorpions develop a clinical syndrome which may require sedation with benzodiazepines and observation for 6 to 28 hours of intensive care monitoring. A safe therapy is necessary to halt the progression of symptoms early in the clinical course while avoiding the clinical deterioration that can occur en route to a tertiary facility. Alacramyn® is anticipated to be safer and more effective than the present standard of care in the United States, midazolam, and faster-acting thus eliminating the need to transport most rural patients and reducing hospitalization time.

Provided treatments

  • Biological: Antivenin Centruroides (scorpion) equine immune F(ab')2
Tris trial is registered with FDA with number: NCT01599923. The sponsor of the trial is Instituto Bioclon S.A. de C.V. and it is looking for 29 volunteers for the current phase.
Official trial title:
Open Label, Confirmatory, Controlled Clinical Study of Alacramyn® in Pediatric Patients With Scorpion Sting Envenomation